Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting.

Author(s): Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, Hernán MA, Lipsitch M, Kohane I, Netzer D, Reis BY, Balicer RDJournal: N Engl J MedPMID: 34432976 August 2021
Preapproval trials showed that messenger RNA (mRNA)-based vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had a good safety…

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers.

Author(s): Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M, Cohen C, Mandelboim M, Gal Levin E, Rubin C, Indenbaum V, Tal I, Zavitan M, Zuckerman N, Bar-Chaim A, Kreiss Y, Regev-Yochay GJournal: N Engl J MedPMID: 34320281 July 2021
Despite the high efficacy of the BNT162b2 messenger RNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), rare breakthrough…

Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host.

Author(s): Choi B, Choudhary MC, Regan J, Sparks JA, Padera RF, Qiu X, Solomon IH, Kuo HH, Boucau J, Bowman K, Adhikari UD, Winkler ML, Mueller AA, Hsu TY, Desjardins M, Baden LR, Chan BT, Walker BD, Lichterfeld M, Brigl M, Kwon DS, Kanjilal S, Richardson ET, Jonsson AH, Alter G, Barczak AK, Hanage WP, Yu XG, Gaiha GD, Seaman MS, Cernadas M, Li JZJournal: N Engl J MedPMID: 33176080 December 2020
A 45-year-old man with severe antiphospholipid syndrome complicated by diffuse alveolar hemorrhage, who was receiving anticoagulation therapy, glucocorticoids, cyclophosphamide, and…

Macrolide and Nonmacrolide Resistance with Mass Azithromycin Distribution.

Author(s): Doan T, Worden L, Hinterwirth A, Arzika AM, Maliki R, Abdou A, Zhong L, Chen C, Cook C, Lebas E, O'Brien KS, Oldenburg CE, Chow ED, Porco TC, Lipsitch M, Keenan JD, Lietman TMJournal: N Engl J MedPMID: 33176084 November 2020
Mass distribution of azithromycin to preschool children twice yearly for 2 years has been shown to reduce childhood mortality in…